-
1 Comment
Hanmi Science Co., Ltd is currently in a long term uptrend where the price is trading 23.6% above its 200 day moving average.
From a valuation standpoint, the stock is 48.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.4.
Hanmi Science Co., Ltd's total revenue rose by 0.0% to $219B since the same quarter in the previous year.
Its net income has increased by 100.1% to $16B since the same quarter in the previous year.
Finally, its free cash flow grew by 252.3% to $4B since the same quarter in the previous year.
Based on the above factors, Hanmi Science Co., Ltd gets an overall score of 5/5.
| ISIN | KR7008930000 |
|---|---|
| Industry | Medical Distribution |
| Sector | Healthcare |
| CurrencyCode | KRW |
| Exchange | KO |
| Beta | 1.13 |
|---|---|
| Market Cap | 3T |
| Dividend Yield | 0.4% |
| Target Price | 32381 |
| PE Ratio | None |
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer. The company also offers drug substances, general medicines, health functional foods, and nutrition and health products and services. In addition, it operates an online pharmacy; and offers pharmaceutical management automation systems. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is based in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 008930.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
